Respiratory Syncytial Virus (RSV) is a highly contagious and seasonal ... at the UNC School of Medicine has shown that human T cells have an important role to play in controlling infection. Subscribe ...

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...

Respiratory syncytial virus (RSV), a common infection in children and senior adults, can also infect nerve cells and trigger inflammation leading to nerve damage, according to a new Tulane ...

Respiratory syncytial virus (RSV ... has been based on moderate to complex techniques performed in a laboratory (cell culture, nucleic acid amplification and immunofluorescence assays); however ...

By studying Chikungunya virus, scientists shed light on how immune responses to viral infections may lead to persistent symptoms of autoimmune disease.

After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus ... helps the virus glom onto and infect cells in the body’s upper airways.

The virus, which is the most common cause of lower respiratory tract infections, can infect nerve cells and trigger inflammation. A recent study has revealed why respiratory syncytial virus (RSV ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

A quadruple whammy of viruses – flu, COVID, norovirus, and respiratory syncytial virus, or RSV – is hitting the U.S. as the year comes to a close. The Centers for Disease Control and ...

What is mResvia used for? mResvia (respiratory syncytial virus vaccine) is commonly given to help prevent lower respiratory tract disease (such as pneumonia or bronchiolitis) caused by ...